Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $71.37, for a total transaction of $1,070,550.00. Following the transaction, the chief executive officer owned 612,540 shares in the company, valued at approximately $43,716,979.80. The trade was a 2.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cameron Turtle also recently made the following trade(s):

• On Wednesday, April 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $49.33, for a total transaction of $739,950.00.
• On Monday, March 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $42.19, for a total transaction of $632,850.00.
• On Monday, February 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $32.80, for a total transaction of $492,000.00.

Spyre Therapeutics Stock Performance

NASDAQ SYRE opened at $69.42 on Friday. Spyre Therapeutics, Inc. has a twelve month low of $12.28 and a twelve month high of $76.00. The stock has a market cap of $5.47 billion, a price-to-earnings ratio of -33.38 and a beta of 3.12. The firm’s 50 day moving average price is $51.75 and its two-hundred day moving average price is $37.36.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). On average, research analysts forecast that Spyre Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

More Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
• Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
• Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (≈$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
• Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
• Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows

Institutional Investors Weigh In On Spyre Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SYRE. Summit Securities Group LLC acquired a new stake in shares of Spyre Therapeutics in the 1st quarter valued at $28,000. Russell Investments Group Ltd. lifted its stake in shares of Spyre Therapeutics by 2,881.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after purchasing an additional 4,092 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Spyre Therapeutics in the 4th quarter valued at $74,000. Tower Research Capital LLC TRC lifted its stake in shares of Spyre Therapeutics by 182.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after purchasing an additional 3,725 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Spyre Therapeutics by 61.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after purchasing an additional 1,435 shares during the last quarter. Institutional investors and hedge funds own 80.39% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on SYRE. Jefferies Financial Group boosted their price target on shares of Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a report on Monday, April 13th. Raymond James Financial began coverage on shares of Spyre Therapeutics in a report on Monday, April 13th. They set a “strong-buy” rating and a $80.00 price target on the stock. Wells Fargo & Company boosted their price target on shares of Spyre Therapeutics from $50.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Spyre Therapeutics from $55.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Finally, Robert W. Baird boosted their price target on shares of Spyre Therapeutics from $65.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Spyre Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $85.08.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.